

## HR 8405

Protecting Access to Medication Abortion Act

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Jul 18, 2022

**Current Status:** Referred to the House Committee on Energy and Commerce.

**Latest Action:** Referred to the House Committee on Energy and Commerce. (Jul 18, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/8405>

### Sponsor

**Name:** Rep. Bush, Cori [D-MO-1]

**Party:** Democratic • **State:** MO • **Chamber:** House

### Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Jul 18, 2022
Rep. Beyer, Donald S., Jr. [D-VA-8]	D · VA		Jul 18, 2022
Rep. Jackson Lee, Sheila [D-TX-18]	D · TX		Jul 18, 2022
Rep. McCollum, Betty [D-MN-4]	D · MN		Jul 18, 2022
Rep. Omar, Ilhan [D-MN-5]	D · MN		Jul 18, 2022

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Jul 18, 2022

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

Bill	Relationship	Last Action
117 S 4467	Identical bill	<b>Jun 23, 2022:</b> Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

## Protecting Access to Medication Abortion Act

This bill directs the Food and Drug Administration (FDA) to take steps to allow patients to receive prescriptions for mifepristone, a drug approved by the FDA for medical abortion, via telehealth and for prescriptions for the drug to be filled by mail.

(Mifepristone is subject to a Risk Evaluation and Mitigation Strategy, which imposes various safety-related requirements. During the COVID-19 public health emergency, the FDA suspended enforcement of the current strategy's requirement that the drug must be dispensed in person, and this suspension is still in effect. In December 2021, the FDA stated the data supported modifying the strategy to remove the in-person dispensing requirement.)

Under this bill, the FDA must require the holder of the relevant approved drug application to submit a proposal to modify the strategy. The modification shall (1) remove the in-person dispensing requirement, (2) allow patients to access prescriptions for mifepristone via telehealth, and (3) authorize all pharmacies certified to dispense mifepristone to patients to do so via mail.

## Actions Timeline

---

- **Jul 18, 2022:** Introduced in House
- **Jul 18, 2022:** Referred to the House Committee on Energy and Commerce.